Corporate News & Publications

CLINUVEL's company releases, including archives.

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its vitiligo program will feature in presentations to be given at this week’s American Academy of Dermatology (AAD) 73rd Annual Meeting in San Francisco. Data from Clinuvel’s vitiligo program will be reviewed and discussed by experts involved in the CUV102 and CUV103 clinical trials, where SCENESSE® has been used as a combination repigmentation treatment for darker skinned vitiligo patients. “We are seeing an increasing recognition of the need to treat vitiligo in practical dermatology, which is reflected in the number of presentations featuring Clinuvel’s program,” Clinuvel’s Director, Clinical…
Thursday, 12 March 2015 07:03

Clinuvel Newsletter - March 2015

Friday, 06 March 2015 18:37

S&P Dow Jones Indices Announces March 2015 Quarterly Rebalance of the S&P/ASX Indices

Monday, 02 March 2015 19:30

Appendix 3B - March 2

Wednesday, 25 February 2015 18:18

Appendix 4D - Half Yearly Report to Dec 31 2014

Friday, 30 January 2015 19:27

Appendix 4C - Q2 FY15

Friday, 23 January 2015 18:36

Appendix 3Y - January 23

Friday, 23 January 2015 18:35

Appendix 3B - January 23

Wednesday, 21 January 2015 17:47

Appendix 3X - Mr Willem Blijdorp

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is pleased to announce the appointment of Mr Willem Blijdorp as a Non-Executive Director of the Company. Mr Blijdorp’s appointment comes as Clinuvel prepares the commercial distribution of SCENESSE® for the rare disease erythropoietic protoporphyria (EPP) throughout the European Union. Mr Blijdorp is the founding member, majority shareholder and a current supervisory Director of B&S International NV, a privately owned Dutch group focused on the wholesale and international trading of luxury and fast moving consumer goods and pharmaceutical products. He managed B&S International for 27 years as CEO and remains actively…

Quick Links